Global drug manufacturers have agreed to cooperate with an independent review of diabetes drugs classified as “incretin mimetics,” which include Byetta and Januvia, in light of a growing body of research suggesting that the drugs may be linked to pancreatic cancer and a potentially deadly inflammation of the pancreas called pancreatitis.
The American Diabetes Association has called for such a review.
A Reuters report on the issue quotes the ADA’s chief scientific ...
continue reading...